The pharmaceutical industry is now a large-scale mergers and acquisitions of multinational pharmaceutical companies, the third in 1 month!

"Pharmaceutical Network Industry Dynamics" Recently, the pharmaceutical industry is now a large-scale mergers and acquisitions of multinational pharmaceutical companies.
September 13, local time, Gilead announced that it would buy biotech company Immunomedics for about $21 billion to acquire Trodelvy, the latter's original drug, to expand its cancer treatment business.
said it would buy for $88 a share in cash, funded by about $15 billion in cash on hand and $6 billion in new debt issuance.
expects the deal to close in the fourth quarter of 2020.
public information, Immunomedics is a company focused on the development, production and commercialization of antibody drug coupleds (ADCs).
April, Trodelvy, the company's first commercial ADC product, received accelerated FDA approval for adult patients with metastatic triple-negative breast cancer (mTNBC) who had previously received at least two treatments for metastatic diseases.
understand that the market value of Immunomedics has risen from $2 billion to nearly $9.8 billion in six months since Trodelvy was approved for listing and clinical progress was announced.
about the deal, Gilead believes it could help the company accelerate its efforts to diversify into the cancer sector.
In fact, Gilead has been moving since the beginning of the year, acquiring 47, cancer therapy biotech companies, Pionyr Immunotherapeutics, cancer immunotherapy developer, and Tizona 49.9% in March, June and July, consolidating its competitiveness in cancer non-cell therapy.
recent years, pharmaceutical companies can be described as mergers and acquisitions, integration action frequently.
, in addition to Gilead, there have been a number of large-scale mergers and acquisitions of multinational pharmaceutical companies.
September 9, Bayer and KaNDy Therapeutics, a British clinical biotech company, announced that Bayer would acquire KaNDy Therapeutics to expand its drug product development pipeline in the field of women's health.
under the terms of the agreement, Bayer will pay $425 million for potential milestone payments of up to $450 million after the product available, and hundreds of millions of dollars in subsequent potential sales milestone payments.
, KaNDy Therapeutics is a clinical biotech company and a subsidiary of NeRRe Therapeutics Ltd.
it is understood that KaNDy Therapeutics has recently completed a clinical study of NT-814's Phase IIb and published positive data on its treatment of common menopausal symptoms, such as hot water and night sweats (vascular shrobbing symptoms).
Phase III clinical trials of the drug are expected to begin in 2021.
approved, the NT-814's global sales potential could peak at more than 1 billion euros.
addition, French pharmaceutical giant Sanofi group announced on August 17th that it would buy Prinshpia Biopharmaceuticals of the United States for $3.68 billion.
the acquisition has now been unanimously approved by both boards of directors.
announced that Sanofi will buy all outstanding shares of Prinshpia Biopharmaceuticals for $100 a share.
deal, which totals about $3.68 billion, is expected to close in the fourth quarter of 2020.
San Francisco, USA, the company focuses on developing treatments for autoimmune diseases, according to a new report.
Sanofi said in a statement that the acquisition will strengthen the Group's research and development in areas such as autoimmune and allergic diseases.
if the deal is successful, Sanofi will get the brain-permeable BTK inhibitor SAR442168, which is used primarily to treat multiple sclerosis and other central nervous system diseases.
2017, Prinsypia licensed Sanofi a global research and development license for the drug.
the acquisition is completed, Sanofi will no longer have to pay the drug royalties for it.